Korsana Biosciences, Inc. Common Stock
KRSA
69 hedge funds and large institutions have $140M invested in Korsana Biosciences, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 10 closing their positions.
33% more capital invested
Capital invested by funds: $105M → $140M (+$35M)
3.91% more ownership
Funds ownership: 63.73% → 67.64% (+3.9%)
1% less funds holding
Funds holding: 70 → 69 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
21% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 24
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$4.08M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$488K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$79K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$48.7K |
| 5 |
Morgan Stanley
New York
|
+$44.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$1.46M |
| 2 |
Renaissance Technologies
New York
|
-$502K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$466K |
| 4 |
AC
AWH Capital
Dallas,
Texas
|
-$310K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$187K |
KRSA Hedge Fund Activity: Q3 2020 in Review
69 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q3 2020, worth a combined $140M — up 33% from $105M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KRSA and 9 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 19 added.
The largest buyer was Slate Path Capital, adding an estimated $4.08M. The largest seller was Eversept Partners, exiting entirely with an estimated $1.46M sold.
- 69 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q3 2020, down from 70 in Q2 2020.
- Funds reported $140M of Korsana Biosciences, Inc. Common Stock stock for Q3 2020, up 33% quarter-over-quarter.
- 9 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q3 2020 and 10 closed out, a net change of -1 holder.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q3 2020 was Slate Path Capital, an estimated $4.08M added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q3 2020 was Eversept Partners, an estimated $1.46M sold.
Based on aggregated 13F filings for Q3 2020.